Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis
Karol A, Fujiwara Y, D'Ovidio T, Baldwin E, Joshi H, Doroshow D, Galsky M. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. Immunotherapy 2024, 16: 829-840. PMID: 39155854, PMCID: PMC11457654, DOI: 10.1080/1750743x.2024.2379230.Peer-Reviewed Original ResearchImmune checkpoint blockadeProgression-free survivalC-reactive proteinPeripheral blood cytokinesOverall survivalTumor-promoting inflammationCheckpoint blockadeInterleukin-6Interleukin-8Blood cytokinesOn-treatment declineIL-8 levelsTrial end pointsIL-6 levelsPharmacodynamic biomarkersInflammatory cytokinesEnd pointsResponse rateCytokinesMeta-analysisSystematic reviewBlockadeInflammationORRSurvivalTrastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.Peer-Reviewed Original ResearchBiliary tract cancerProgression-free survivalT-DXdPancreatic cancerHER2 expressionEfficacy outcomesDrug-related interstitial lung diseaseOpen-label phase 2 studyPC cohortDrug-related adverse eventsLate-line treatmentPrimary tumor locationPhase 2 studyGrade (GClinically meaningful benefitInterstitial lung diseaseHER2-expressing tumorsAdvanced/metastatic diseaseData cutoffIHC 3PD-L1Trastuzumab deruxtecanExploratory endpointsTumor locationPrimary endpointEfficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Wysocki P, Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, SU P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Fielding A, Jung L, Michelini F, Puvvada S, Makker V. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Journal Of Clinical Oncology 2024, 42: 4565-4565. DOI: 10.1200/jco.2024.42.16_suppl.4565.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalDuration of responseT-DXdPretreated ptsHER2 expressionUrothelial cancerBladder cohortEfficacy outcomesSolid tumorsSafety of trastuzumab deruxtecanDrug-related adverse eventsPhase 2 studyClinically meaningful responseGrade (GHER2 expression levelsTrastuzumab deruxtecanAdvanced/metastatic diseaseData cutoffPD-L1Open-labelExploratory endpointsPrimary endpointSystemic treatmentSecondary endpointsC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatients